LXRX News and Press, Lexicon Pharmaceuticals Inc. From 12/16/20

THE WOODLANDS, Texas, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any...

Lexicon shares have shot higher in just a month, buoyed by an FDA Fast Track designation for LX9211 and positive clinical data from sotagliflozin. Multiple SGLT-2 inhibitors have shown cardiac outcome benefits, and I remain unconvinced that sotagliflozin can separate itself from the p...

Lexicon Pharmaceuticals (NASDAQ: LXRX) ended Friday 6% lower than the previous close. A fall seemed inevitable, as the company announced a rather dilutive new secondary common stock issue at a level below the shares' Thursday closing price. Lexicon, a biotech focused on developi...

Lexicon Pharmaceuticals (LXRX) inks agreement with institutional investors providing for the purchase and sale, in a registered direct offering, of ~20.31M shares of common stock at a price of $3.20 per share, for aggregate gross proceeds of $65M.Closing date is December 16.Earlier today, the...

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale, in a registered direct offering, of 20,312,...

In the past few weeks, we have seen a great amount of bullish interest in penny stocks . Specifically, there are a few key markets that have seen more bullish growth than others. First, we have biotech penny stocks. These companies have experienced growth in the past six months due to t...

Lexicon Pharmaceuticals (LXRX) soars 44% premarket after has receiving Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain.Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of ...

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. ...

Oncternal Therapeutics (ONCT) -25% on increasing previously announced bought deal offer to $75.0M.GeoVax Labs (GOVX) -23%.Xenetic Biosciences (XBIO) -21%. on launching $6M registered direct offering priced at-the-market.Savara (SVRA) -19% on providing pipeline and business...

Palm Beach, FL –December 9, 2020 – In the breast cancer therapy market, the rise in the healthcare awareness among individual’s disease and treatment, early detection of the cancer, better surgical and medical treatment, R&D initiatives, and technological advancemen...